| Title: |
Healthcare Resource Consumption and Related Costs in Patients on Antiretroviral Therapies: Findings from Real-World Data in Italy |
| Authors: |
Perrone V.; Dovizio M.; Sangiorgi D.; Andretta M.; Bartolini F.; Cavaliere A.; Ciaccia A.; Chinellato A.; Costantini A.; Dell'Orco S.; Ferrante F.; Gentile S.; Lavalle A.; Moscogiuri R.; Mosele E.; Procacci C.; Re D.; Santoleri F.; Roccia A.; Maggiolo F.; Degli Esposti L. |
| Contributors: |
Perrone, V.; Dovizio, M.; Sangiorgi, D.; Andretta, M.; Bartolini, F.; Cavaliere, A.; Ciaccia, A.; Chinellato, A.; Costantini, A.; Dell'Orco, S.; Ferrante, F.; Gentile, S.; Lavalle, A.; Moscogiuri, R.; Mosele, E.; Procacci, C.; Re, D.; Santoleri, F.; Roccia, A.; Maggiolo, F.; Degli Esposti, L. |
| Publication Year: |
2023 |
| Collection: |
ARUd'A - Archivio Istituzionale della ricerca dell'università Chieti-Pescara (IRIS) |
| Subject Terms: |
adherence; antiretroviral therapies (ART); direct healthcare cost; drug utilization; healthcare resource consumption; human immunodeficiency virus (HIV); persistence; real-word evidence; tenofovir alafenamide (TAF)-based regimens |
| Description: |
This real-world analysis conducted on administrative databases of a sample of Italian healthcare entities was aimed at describing the role of therapeutic pathways and drug utilization in terms of adherence, persistence, and therapy discontinuation in HIV-infected patients under antiretroviral therapies (ART) and Tenofovir Alafenamide (TAF)-based regimens on healthcare resource consumption and related direct healthcare costs. Between 2015 and 2019, adults (≥18 years) prescribed with TAF-based therapies were identified and characterized in the year prior to the first prescription (index-date) for TAF-based therapies and followed-up until the end of data availability. Overall, 2658 ART-treated patients were included, 1198 of which were under a TAF-based regimen. TAF-based therapies were associated with elevated percentages of adherence (83.3% patients with proportion of days covered, PDC > 95% and 90.6% with PDC > 85%) and persistence (78.5%). The discontinuation rate was low in TAF-treated patients, ranging from 3.3% in TAF-switchers to 5% in naïve. Persistent patients had lower overall mean annual healthcare expenditures (EUR 11,106 in persistent vs. EUR 12,380 in non-persistent, p = 0.005), and this trend was statistically significant also for costs related to HIV hospitalizations. These findings suggest that a better therapeutic management of HIV infection might result in positive clinical and economic outcomes. |
| Document Type: |
article in journal/newspaper |
| File Description: |
ELETTRONICO |
| Language: |
English |
| Relation: |
volume:20; issue:5; numberofpages:12; journal:INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH; https://hdl.handle.net/11564/828757 |
| DOI: |
10.3390/ijerph20053789 |
| Availability: |
https://hdl.handle.net/11564/828757; https://doi.org/10.3390/ijerph20053789; https://www.mdpi.com/1660-4601/20/5/3789 |
| Rights: |
info:eu-repo/semantics/openAccess |
| Accession Number: |
edsbas.EE3FEADE |
| Database: |
BASE |